Autopsy report · NCT01882231

Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma

“Slow accrual and lack of funding”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 3 years 1 month before it stopped.
• 6 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Vanderbilt-Ingram Cancer Center

Sponsor type

University, hospital or other

Conditions

Osteosarcoma; Paget's Disease; Ewing Sarcoma

Interventions

DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
  “Lack of funding and slow accrual” (97% match in meaning)
• Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma
  “Limited funding, slow accrual” (92% match in meaning)
• Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy
  “Slow accrual and funding limitations.” (90% match in meaning)
• Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure
  “slow accrual; insufficient funding to continue to accrue” (88% match in meaning)
• Adolescent Daughters' Response and Adjustment to Maternal Breast Cancer
  “due to slow accrual and lack of funding” (88% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.